Immuneoncia
2 known investors
Immuneoncia develops immuno-oncology cancer therapeutics, including antibody drugs targeting PD-L1 and CD47, with a program targeting both CD47 and PD-L1 simultaneously. Based in South Korea, the company works to advance immune-based cancer treatments.
Investors · 2
In the news
Frequently asked questions
- What does Immuneoncia do?
- Immuneoncia develops immuno-oncology cancer therapeutics, including antibody drugs targeting PD-L1 and CD47, with a program targeting both CD47 and PD-L1 simultaneously. Based in South Korea, the company works to advance immune-based cancer treatments.
- Who are Immuneoncia's investors?
- Immuneoncia's investors include LB Investment, Premier Partners.